BRITISH pharmaceuticals firm Clinigen yesterday agreed to buy smaller Aim-listed rival Quantum Pharma for £150.3m.
Clinigen, which specialises in the supply of unlicensed medicines to doctors and hospitals, said the acquisition will put it in a stronger position to drive its global expansion.
Under the deal, Quantum shareholders will receive 37p in cash and 0.0405 new Clinigen shares for each Quantum share held. Based on Clinigen's closing price on Tuesday of 1,111p, that values eac
RelSci News & Alerts gets you:
- 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
- Competitive business intelligence through daily data updates
- Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox